keyword
MENU ▼
Read by QxMD icon Read
search

obesity AND GLP-1

keyword
https://www.readbyqxmd.com/read/29772784/capsaicin-in-metabolic-syndrome
#1
REVIEW
Sunil K Panchal, Edward Bliss, Lindsay Brown
Capsaicin, the major active constituent of chilli, is an agonist on transient receptor potential vanilloid channel 1 (TRPV1). TRPV1 is present on many metabolically active tissues, making it a potentially relevant target for metabolic interventions. Insulin resistance and obesity, being the major components of metabolic syndrome, increase the risk for the development of cardiovascular disease, type 2 diabetes, and non-alcoholic fatty liver disease. In vitro and pre-clinical studies have established the effectiveness of low-dose dietary capsaicin in attenuating metabolic disorders...
May 17, 2018: Nutrients
https://www.readbyqxmd.com/read/29768729/adaptive-changes-in-pancreas-post-roux-en-y-gastric-bypass-induced-weight-loss
#2
A Lautenbach, M Wernecke, N Riedel, J Veigel, J Yamamura, S Keller, R Jung, P Busch, O Mann, F K Knop, J J Holst, J J Meier, J Aberle
AIMS: Obesity has been shown to trigger adaptive increases in pancreas parenchymal and fat volume. Consecutively, pancreatic steatosis may lead to beta-cell dysfunction. However, it is not known, whether the pancreatic tissue components decrease with weight loss and pancreatic steatosis is reversible following RYGB. Therefore, the objective of the study was to investigate the effects of RYGB-induced weight loss on pancreatic volume and glucose homeostasis. MATERIALS AND METHODS: 11 patients were recruited in the Obesity Centre of the University Medical Centre Hamburg-Eppendorf...
May 16, 2018: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/29759973/enhanced-glucose-control-following-vertical-sleeve-gastrectomy-does-not-require-a-%C3%AE-cell-glucagon-like-peptide-1-receptor
#3
Jonathan D Douros, Alfor G Lewis, Eric P Smith, JingJing Niu, Megan Capozzi, April Wittmann, Jonathan Campbell, Jenny Tong, Constance Wagner, Parinaz Mahbod, Randy Seeley, David A D'Alessio
Bariatric surgeries, including vertical sleeve gastrectomy (VSG), resolve diabetes in 40-50% of patients. Studies examining the molecular mechanisms underlying this effect have centered on the role of the insulinotropic glucagon-like peptide 1 (GLP-1), in great part because of the ∼10-fold rise in its circulating levels after surgery. However, there is currently debate over the role of direct β-cell signaling by GLP-1 to mediate improved glucose tolerance following surgery. In order to assess the importance of β-cell GLP-1 receptor (GLP-1R) for improving glucose control after VSG, a mouse model of this procedure was developed and combined with a genetically modified mouse line allowing an inducible, β-cell specific Glp1r knockdown ( Glp1r β-cell-ko )...
May 14, 2018: Diabetes
https://www.readbyqxmd.com/read/29744819/comparison-of-glycemic-variability-in-chinese-t2dm-patients-treated-with-exenatide-or-insulin-glargine-a-randomized-controlled-trial
#4
Ting-Ting Yin, Yan Bi, Ping Li, Shan-Mei Shen, Xiao-Lu Xiong, Li-Jun Gao, Can Jiang, Yan Wang, Wen-Huan Feng, Da-Long Zhu
INTRODUCTION: Increasing the frequency of blood glucose monitoring aids the evaluation of glycemic variability and blood glucose control by antidiabetic drugs. It remains unclear, however, whether GLP-1 receptor agonists or basal insulin has a better effect on glycemic variability in type 2 diabetes mellitus (T2DM) patients who are inadequately controlled by metformin. We used a continuous glucose monitoring system (CGMS) to compare patients on a GLP-1 receptor agonist with patients on basal insulin in terms of glycemic variability...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29737256/cardiovascular-effects-of-liraglutide
#5
Nasser Mikhail
BACKGROUND: Liraglutide is a glucagon-like 1 (GLP-1) agonist approved for treatment of type 2 diabetes and obesity. OBJECTIVE: To review the cardiovascular effects of liraglutide including macrovascular and microvascular events, its use in heart failure, and its effects on heart rate and blood pressure. RESULTS: The impact of liraglutide on cardiovascular outcomes was examined in a large well-designed study published in 2016, the LEADER trial...
May 7, 2018: Current Hypertension Reviews
https://www.readbyqxmd.com/read/29729352/pegylated-prodrugs-of-antidiabetic-peptides-amylin-and-glp-1
#6
Roland Böttger, Daniel Knappe, Ralf Hoffmann
Agonists of the glucagon-like peptide-1 (GLP-1) receptor and analogs of human amylin have been studied for almost two decades due to their therapeutic potential to treat diabetes mellitus and obesity. Both native peptides exhibit unfavorable pharmacokinetics. Even optimized analogs less prone to proteolysis have to be applied at least daily or once-weekly utilizing microsphere formulations or fusion to proteins. Thus, innovative approaches allowing tuning the drug levels to achieve beneficial therapeutic responses and prolonged application intervals are demanded...
May 2, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29725251/glucagon-like-peptide-1-receptor-agonist-and-glucagon-increase-glucose-stimulated-insulin-secretion-in-beta-cells-via-distinct-adenylyl-cyclases
#7
Young-Sun Lee, Hee-Sook Jun
Diabetes mellitus is a chronic disease in which the pancreas no longer produces enough insulin. Pancreatic alpha cell mass increases in response to insufficient insulin secretion. However, the reason for this increase is not clear. It is possible that the increased alpha-cells may stimulate compensatory insulin release in response to the insufficient insulin such as insulin resistance. In this study, we investigated whether glucagon and glucagon-like peptide-1 (GLP-1), hormones produced by alpha cells, contribute to insulin secretion in INS-1 cells, a beta cell line...
2018: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29705602/liraglutide-attenuates-the-depressive-and-anxiety-like-behaviour-in-the-corticosterone-induced-depression-model-via-improving-hippocampal-neural-plasticity
#8
Han Weina, Niu Yuhu, Holscher Christian, Li Birong, Shen Feiyu, Wang Le
Recent studies indicate that metabolic disorders such as diabetes and obesity are a major risk factor of psychiatric diseases. This relationship opens the opportunity to develop new antidepressant drugs by repurposing antidiabetic drugs. Previous research has demonstrated that GLP-1 analogs are neuroprotective in several neurological disease models including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke. In addition, the GLP-1 analog liraglutide has been shown to promote neurogenesis, which is seen to play important roles in memory formation and cognitive and emotional processing...
April 26, 2018: Brain Research
https://www.readbyqxmd.com/read/29703793/liraglutide-increases-ivf-pregnancy-rates-in-obese-pcos-women-with-poor-response-to-first-line-reproductive-treatments-a-pilot-randomized-study
#9
Vesna Salamun, Mojca Jensterle, Andrej Janez, Eda Vrtacnik Bokal
OBJECTIVE: Glucagon-like peptide-1 (GLP-1) has been investigated in regulation of reproductive system in animal models. The potential impact of short-term preconception intervention with liraglutide on fertility potential in PCOS has not been evaluated yet. DESIGN: A prospective randomized open-label study was conducted in 28 infertile obese PCOS patients (age 31.07±4.75 years, BMI 36.7±3.5 kg/m2, mean±SD). They were assigned to metformin (MET) 1000 mg BID or to MET 1000 mg BID combined with low-dose liraglutide 1...
April 27, 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29703503/fasting-levels-of-glicentin-are-higher-in-roux-en-y-gastric-bypass-patients-exhibiting-postprandial-hypoglycemia-during-a-meal-test
#10
Christine Poitou, Elodie Bouaziz-Amar, Laurent Genser, Jean-Michel Oppert, Jean-Marc Lacorte, Johanne Le Beyec
BACKGROUND: Post-bypass postprandial hypoglycemia (PPH) is a frequent complication of Roux-en-Y Gastric Bypass (RYGB) but predictors remain poorly identified and are needed to assess individual risk. After RYGB, exaggerated secretion of glucagon-like peptide-1 (GLP-1) and insulin could lead to PPH, but other proglucagon-derived peptides, including glicentin and glucagon, could also contribute to this phenomenon. OBJECTIVES: To identify biological hypoglycemia in relation to the secretion of proglucagon-derived peptides during a mixed-meal test (MMT) in RYGB patients...
March 19, 2018: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/29698465/barley-%C3%AE-glucan-improves-metabolic-condition-via-short-chain-fatty-acids-produced-by-gut-microbial-fermentation-in-high-fat-diet-fed-mice
#11
Junki Miyamoto, Keita Watanabe, Satsuki Taira, Mayu Kasubuchi, Xuan Li, Junichiro Irie, Hiroshi Itoh, Ikuo Kimura
Dietary intake of barley β-glucan (BG) is known to affect energy metabolism. However, its underlying mechanism remains poorly understood because studies have presented inconsistent results, with both positive and negative effects reported in terms of satiety, energy intake, weight loss, and glycemic control. The objective of this study was to clarify the physiological role underlying the metabolic benefits of barley BG using a mouse model of high fat diet (HFD)-induced obesity. Male 4-wk-old C57BL/6J mice were fed an HFD with 20% barley flour containing either high BG (HBG; 2% BG) or low BG (LBG; 0...
2018: PloS One
https://www.readbyqxmd.com/read/29688303/free-fatty-acid-receptors-in-enteroendocrine-cells
#12
Van B Lu, Fiona M Gribble, Frank Reimann
Free fatty acid receptors (FFAs) are highly enriched in enteroendocrine cells providing pathways to link dietary fats and microbially-generated short chain fatty acids (SCFA) to the secretion of a variety of gut hormones. FFA1 and FFA4 are receptors for long chain fatty acids that have been linked to the elevation of plasma gut hormones after fat ingestion. FFA2 and FFA3 are receptors for SCFA, which are generated at high concentrations by microbial fermentation of dietary fibre, and have also been implicated in enhancement of gut hormone secretion...
April 23, 2018: Endocrinology
https://www.readbyqxmd.com/read/29680267/oxyntomodulin-analogue-increases-energy-expenditure-via-the-glucagon-receptor
#13
R Scott, J Minnion, T Tan, S R Bloom
The gut hormone oxyntomodulin (OXM) causes weight loss by reducing appetite and increasing energy expenditure. Several analogues are being developed to treat obesity. Exactly how oxyntomodulin works, however, remains controversial. OXM can activate both glucagon and GLP-1 receptors but no specific receptor has been identified. It is thought that the anorectic effect occurs predominantly through GLP-1 receptor activation but, to date, it has not been formally confirmed which receptor is responsible for the increased energy expenditure...
April 19, 2018: Peptides
https://www.readbyqxmd.com/read/29678867/effect-of-the-duodenal-jejunal-bypass-liner-on-glycemic-control-in-patients-with-type-2-diabetes-with-obesity-a-meta-analysis-with-secondary-analysis-on-weight-loss-and-hormonal-changes
#14
REVIEW
Pichamol Jirapinyo, Andrea V Haas, Christopher C Thompson
OBJECTIVE: Duodenal-jejunal bypass liner (DJBL) is an endoscopic device that may mimic small bowel mechanisms of Roux-en-Y gastric bypass (RYGB). Previous studies have demonstrated the efficacy of DJBL at inducing weight loss. We assessed the effect of DJBL on glycemic control in patients with type 2 diabetes (T2D) with obesity. RESEARCH DESIGN AND METHODS: Data sources included MEDLINE, EMBASE, and Web of Science through 1 July 2017. Included were published studies that assessed DJBL outcomes in obese T2D patients...
May 2018: Diabetes Care
https://www.readbyqxmd.com/read/29673717/novel-fatty-acid-chain-modified-glp-1-derivatives-with-prolonged-in-vivo-glucose-lowering-ability-and-balanced-glucoregulatory-activity
#15
Xingguang Cai, Lidan Sun, Yuxuan Dai, Yosefa Avraham, Chunxia Liu, Jing Han, Yuan Liu, Dazhi Feng, Wenlong Huang, Hai Qian
Glucagon-like peptide-1 is a potent hypoglycemic hormone with beneficial properties for the treatment of diabetes. However, its half-life is short because the rapid metabolic degradation. This study aims to prolong the half-life of glucagon-like peptide-1 through conjugation with the fatty acid side chain which helps the conjugates to interact with the albumin. Firstly, we chose two optimized polypeptide chains which have tremendous hypoglycemic effect named Cys17 -Gly8 -GLP-1(7-36)-NH2 and Cys37 -Gly8 -GLP-1(7-37)-NH2 , and various fatty acid chains were modified...
April 11, 2018: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/29667023/liraglutide-effects-on-upper-gastrointestinal-investigations-implications-prior-to-bariatric-surgery
#16
Renuca Modi, Peter Rye, Sarah Cawsey, Daniel W Birch, Arya M Sharma
Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue that is approved for long-term obesity management in North America. While bariatric surgery remains the gold standard for weight loss, an increasing number of patients are on liraglutide in the setting of ongoing workup for bariatric surgery. The presence of gastrointestinal symptoms prior to bariatric surgery may prompt testing for dysmotility, which affects surgical decision making. Here we report six cases where treatment with liraglutide was associated with reversible reduction in gastric and esophageal motility in screening for bariatric surgery...
April 17, 2018: Obesity Surgery
https://www.readbyqxmd.com/read/29660230/the-use-of-antimicrobials-as-adjuvant-therapy-for-the-treatment-of-obesity-and-insulin-resistance-effects-and-associated-mechanisms
#17
REVIEW
Sandra Aparecida Dos Reis, Maria do Carmo Gouveia Peluzio, Josefina Bressan
The intestinal microbiota has come to be considered an additional risk factor for the development of metabolic diseases. Considering the potential role of antimicrobials as modulators of the intestinal microbiota, they have been investigated for use in the adjuvant treatment of obesity and insulin resistance. In this regard, the present manuscript aimed to review the effect of regular use of antimicrobials on the treatment of obesity and/or IR, as well as its associated mechanisms. The regular use of antimicrobials does not seem to influence the body weight and adiposity of its consumer...
April 16, 2018: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/29617641/mechanisms-of-action-and-therapeutic-application-of-glucagon-like-peptide-1
#18
REVIEW
Daniel J Drucker
Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion. GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting weight gain. Here I review the circuits engaged by endogenous versus pharmacological GLP-1 action, highlighting key GLP-1 receptor (GLP-1R)-positive cell types and pathways transducing metabolic and non-glycemic GLP-1 signals...
April 3, 2018: Cell Metabolism
https://www.readbyqxmd.com/read/29598932/glucagon-like-peptide-1-glp-1-likes-alzheimer-s-disease
#19
REVIEW
Ilgin Yildirim Simsir, Utku Erdem Soyaltin, Sevki Cetinkalp
Glucagon-like peptide-1 (GLP-1) is a 30 amino acid long peptide hormone derived from the proglucagon gene and secreted in the distal small intestine when food enters the duodenum. GLP-1 is also produced in the central nervous system (CNS), predominantly in the brainstem, and subsequently transported to a large number of regions in the CNS. Neuronal cells in nucleus tractus solitarius (NTS) can synthesize GLP-1 and extends to hypothalamus, some thalamic and cortical areas. A G protein coupled receptor (GPCR) provides the majority of GLP-1 actions...
March 16, 2018: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/29596853/exenatide-has-a-pronounced-effect-on-energy-intake-but-not-energy-expenditure-in-non-diabetic-subjects-with-obesity-a-randomized-double-blind-placebo-controlled-trial
#20
Alessio Basolo, Joshua Burkholder, Kristy Osgood, Alexis Graham, Sarah Bundrick, Joseph Frankl, Paolo Piaggi, Marie S Thearle, Jonathan Krakoff
AIMS: Exenatide is a glucagon-like peptide 1 (GLP-1) mimetic which induces weight loss predominantly, it is presumed, via decreased food intake. However, circulating GLP-1 is also a determinant of energy expenditure. We sought to quantify the effect of exenatide on energy expenditure (EE) and energy intake. MATERIALS AND METHODS: In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34...
March 26, 2018: Metabolism: Clinical and Experimental
keyword
keyword
25085
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"